Sintx Technologies (SINT) Expected to Announce Quarterly Earnings on Monday

Sintx Technologies (NASDAQ:SINT) is expected to post its results before the market opens on Monday, March 30th. Analysts expect Sintx Technologies to post earnings of ($0.55) per share and revenue of $0.30 million for the quarter.

Sintx Technologies Stock Performance

SINT stock opened at $2.28 on Friday. The company has a market capitalization of $9.39 million, a P/E ratio of -0.40 and a beta of 0.67. The company has a fifty day moving average price of $2.96 and a 200-day moving average price of $3.52. Sintx Technologies has a 52-week low of $1.71 and a 52-week high of $6.78.

Hedge Funds Weigh In On Sintx Technologies

A hedge fund recently raised its stake in Sintx Technologies stock. Geode Capital Management LLC increased its stake in shares of Sintx Technologies, Inc. (NASDAQ:SINT) by 33.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,339 shares of the company’s stock after acquiring an additional 3,848 shares during the quarter. Geode Capital Management LLC owned approximately 0.56% of Sintx Technologies worth $49,000 at the end of the most recent quarter. Institutional investors and hedge funds own 18.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SINT. Ascendiant Capital Markets cut their target price on Sintx Technologies from $25.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, December 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Sintx Technologies in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $16.00.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.